Protection of ovarian function by two distinct methods of ovarian shielding for young female patients who receive total body irradiation
- 350 Downloads
To prevent ovarian dysfunction due to total body irradiation, we started ovarian shielding at our center (Saitama Medical Center, Jichi Medical University (SMC-JMU)) with a long source axis distance, which is different from the original method used at the University of Tokyo Hospital (UTH). We retrospectively analyzed the outcome of eight patients with a median age of 20.5 years from SMC-JMU and compared the results with the published data for eight patients with a median age of 22 years from UTH. The recovery of ovarian function was observed in five and six patients, respectively. The cumulative incidence of ovarian recovery, while treating relapse and death without ovarian recovery as competing risks, was 68.8 % at 2 years after transplantation in the total population, and there was no statistically significant difference between the two institutions (p = 0.85). Age and the history of previous chemotherapy did not affect the incidence of ovarian recovery. Two patients from each center had a relapse of leukemia. Overall, among the 11 patients who have survived without relapse, only one has not achieved ovarian recovery. In conclusion, ovarian shielding with both methods strongly protected ovarian function. However, we should continue to monitor the relapse rate among patients who undergo this procedure.
KeywordsHematopoietic stem cell transplantation Fertility Total body irradiation Shielding Ovarian function
Authors thank Shinobu Nakabayashi, Hitoshi Matsuzaki, and Masato Sagehashi for their expert technical support to perform ovarian shielding.
- 6.Courbiere B, Prebet T, Mozziconacci MJ, Metzler-Guillemain C, Saias-Magnan J, Gamerre M (2010) Tumor cell contamination in ovarian tissue cryopreserved before gonadotoxic treatment: should we systematically exclude ovarian autograft in a cancer survivor? Bone Marrow Transplant 45(7):1247–1248. doi: 10.1038/bmt.2009.313 PubMedCrossRefGoogle Scholar
- 7.Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K (2013) Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510. doi: 10.1200/JCO.2013.49.2678 PubMedCrossRefGoogle Scholar
- 8.Nakagawa K, Kanda Y, Yamashita H, Hosoi Y, Oshima K, Ohtomo K, Ban N, Yamakawa S, Nakagawa S, Chiba S (2006) Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation: a report of two successful cases. Bone Marrow Transplant 37(6):583–587PubMedCrossRefGoogle Scholar
- 9.Nakagawa K, Kanda Y, Yamashita H, Nakagawa S, Sasano N, Ohtomo K, Oshima K, Kumano K, Ban N, Nannya Y, Kurokawa M, Chiba S (2008) Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic SCT recipients undergoing TBI. Bone Marrow Transplant 42(10):697–699. doi: 10.1038/bmt.2008.234 PubMedCrossRefGoogle Scholar
- 11.Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZK' for medical statistics. Bone Marrow Transplant 48(3):452–458Google Scholar
- 12.Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20(1):128–135. doi: 10.1038/sj.leu.2404010 PubMedCrossRefGoogle Scholar
- 13.Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M (2008) Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 83(3):226–232. doi: 10.1002/ajh.21087 PubMedCrossRefGoogle Scholar